No results for ‘’
Glenmark Pharmaceuticals Ltd
₹2233.90
(1.99%)
Tue, 04 Aug 2026, 09:17 am
Health Technology
Pharmaceuticals: Major
24.5KGlenmark Pharmaceuticals Return on Equity (ROE) History
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 49.02 | 26.38 | 19.66 | 21.04 | 21.44 | 16.92 | 18.09 | 20.39 | 28.30 | 44.86 | 31.77 | 26.43 | 19.22 | 19.69 | 7.49 | 13.51 | 13.25 | 44.14 | 0 | 41.51 |
| Price to book ratio | 10 | 10.67 | 8.04 | 2.47 | 3.05 | 3.76 | 3.47 | 4.53 | 5.14 | 7.11 | 5.25 | 4.90 | 2.66 | 3.25 | 0.96 | 1.86 | 1.37 | 1.38 | 3.44 | 4.91 |
| Price to sales ratio | 6.27 | 6.86 | 6.43 | 1.97 | 2.86 | 2.60 | 2.07 | 2.50 | 2.59 | 3.27 | 2.95 | 2.67 | 1.64 | 1.87 | 0.55 | 1.21 | 1.01 | 1.13 | 2.29 | 3.26 |
| Price to cash flow ratio | 0 | 147.77 | 40.23 | 0 | 37.10 | 9.73 | 12.85 | 24.70 | 23.04 | 69.95 | 128.71 | 49.13 | 10.30 | 17.22 | 5.30 | 15.59 | 14.38 | 38.94 | 0 | 0 |
| Enterprise value | 4885Cr | 8988Cr | 13259Cr | 6049Cr | 8728Cr | 9613Cr | 10274Cr | 14712Cr | 17807Cr | 24350Cr | 25432Cr | 27876Cr | 18281Cr | 21658Cr | 9880Cr | 16945Cr | 15374Cr | 16925Cr | 26584Cr | 44222Cr |
| Enterprise value to EBITDA ratio | 36.21 | 21.18 | 16.68 | 13.51 | 13.44 | 16.23 | 14.38 | 14.57 | 13.73 | 21.28 | 17.75 | 13.69 | 11.30 | 14.66 | 6.05 | 8.04 | 6.49 | 10.13 | 21.58 | 18.56 |
| Debt to equity ratio | 1.87 | 1.36 | 0.65 | 1.31 | 0.79 | 1.04 | 0.93 | 1 | 1.10 | 1.27 | 0.93 | 0.96 | 0.83 | 0.79 | 0.85 | 0.71 | 0.44 | 0.49 | 0.16 | 0.28 |
| Return on equity % | 24.37 | 57.45 | 57.36 | 12.30 | 16.41 | 20.64 | 20.74 | 23.81 | 18.87 | 15.89 | 19.31 | 19.89 | 14.71 | 16.53 | 12.86 | 14.77 | 11.66 | -1.83 | -21.93 | 12.54 |
Glenmark Pharmaceuticals Ltd Return on Equity
The Glenmark Pharmaceuticals Ltd Return on Equity is a key financial metric used by investors to evaluate Glenmark Pharmaceuticals Ltd's valuation, profitability, and overall financial performance. Tracking the Glenmark Pharmaceuticals Ltd Return on Equity helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Glenmark Pharmaceuticals Ltd (NSE: GLENMARK, BSE: 532296) is currently trading at ₹2233.90, with a market capitalization of ₹63023.91Cr. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Glenmark Pharmaceuticals Ltd Return on Equity is essential for fundamental analysis.
Glenmark Pharmaceuticals Ltd Return on Equity Current Value
The current Glenmark Pharmaceuticals Ltd Return on Equity stands at 12.54.
The latest Glenmark Pharmaceuticals Ltd Return on Equity has increased compared to the previous period, indicating rising valuation or improved investor sentiment.
Glenmark Pharmaceuticals Ltd Return on Equity Historical Trend
The Glenmark Pharmaceuticals Ltd Return on Equity has shown the following historical trend:
- 2024: 12.54
- 2023: -21.93
- 2022: -1.83
- 2021: 11.66
- 2020: 14.77
The recent rise in Glenmark Pharmaceuticals Ltd Return on Equity suggests strengthening valuation trends and improving market sentiment.
What Glenmark Pharmaceuticals Ltd Return on Equity Indicates for Investors
The Glenmark Pharmaceuticals Ltd Return on Equity plays a crucial role in understanding the company's financial health and valuation.
ROE indicates how efficiently the company generates returns for shareholders.
Glenmark Pharmaceuticals Ltd Return on Equity Analysis Summary
The Glenmark Pharmaceuticals Ltd Return on Equity remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Glenmark Pharmaceuticals Ltd Return on Equity should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Glenmark Pharmaceuticals Ltd Return on Equity helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.